Contest Trader

Don't miss the chance to cash-in prizes totaling

$10.000
Register here for the Ultimate demo trading competition

Future COVID-19 vaccine possibly priced under €10

Future COVID-19 vaccine possibly priced under €10

Sanofi is considering releasing an active pharmaceutical company

A few days after they announced that their joint vaccine would undergo human clinical trials, Sanofi and GSK started the week with additional news regarding the vaccine.

Oliver Bogillot, Sanofi’s French CEO, announced that the vaccine's price would be 10 or less. Despite the announcement, he iterated the fact that the final price hadn't been set yet.

Besides the price, the Sanofi plans to list its active pharmaceutical ingredients (API) company publicly. The initial public offering is scheduled to happen in the following months, and the new business could be valued at up to 2billion.

It is the embodiment of a plan touted in February, through which Sanofi will create a standalone company by reuniting under the same roof its commercial and development activities and the power of its six European production sites.

According to Sanofi, the move would balance the industry's reliance on Asia for ingredients, which lately has been disrupted by the pandemic. The drugmaker said that it is taking into consideration a 2022 Euronext Paris listing. If it does it, the new API would be the second-largest in the world after the Swiss Lonza.

Following the news, Sanofi stock price gained 2%.

Sources: marketwatch.com, finance.yahoo.com

Maklumat yang disediakan oleh za.capex.com bukan berbentuk tawaran atau permintaan untuk tujuan pembelian atau penjualan apa-apa produk kewangan yang disebutkan di sini atau melibatkan perundngan, atau nasihat mahupun cadangan berkenaan dengan kewangan produk tersebut.

Maklumat ini disediakan untuk edaran umum. Ia tidak mengambil kira objektif pelaburan tertentu, keadaan kewangan atau keperluan tertentu dari mana-mana penerima.

Anda harus bebas menilai setiap produk kewangan dan mempertimbangkan kesesuaian produk kewangan sedemikian, dengan mengambil kira objektif pelaburan tertentu anda, keadaan kewangan atau keperluan khusus, dan berunding dengan penasihat kewangan bebas, sebelum berurusan dalam produk kewangan yang disebutkan dalam dokumen ini.

Maklumat ini tidak boleh diterbitkan, diedar semula, diterbitkan semula atau diedarkan secara keseluruhan atau sebahagian kepada mana-mana individu lain tanpa kebenaran bertulis daripada Syarikat terlebih dahulu.

Prestasi lalu tidak sentiasa menggambarkan prestasi atau kemungkinan masa depan. Sebarang pandangan atau pendapat yang dikemukakan hanyalah pandangan penulis semata-mata dan tidak mewakili za.capex.com